McN3716 is a carnitine palmitoyltransferase I (CPT-1) inhibitor for the study of metabolic diseases.

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

Significantly reducing the levels of all measured HETE and epoxytrienoic acids (EET), nonenzymatic auto-oxidative metabolites of ARA, by 23% to 44% and 32% to 50% compared with vehicle-injected rats, McN3716 (Methyl palmoxirate, MEP) achieves inhibition of brain mitochondrial β-oxidation. Notably, 15-HETE remains unaffected. McN3716 treatment leads to a significant 34% reduction in the level of 6-keto-PGF1α, a byproduct of PGI2 (prostacyclin). Similarly, the brain level of hydroxyeicosapentaenoic acids, nonenzymatic auto-oxidative metabolites of EPA, is reduced by 35% to 76% upon McN3716 treatment relative to the vehicle[1].